Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Stocks to Love in 2026

View original at nasdaq.com
Stocks to Love in 2026 In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss: Why space is worth watching in 2026.Opportunities in healthcare.How Hims & Hers is disrupting the healthcare industry To catch full episodes of all The Motley Fool's free podcasts, check out our podca…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Redwire is owning the fundamental building blocks if we're going to have a Golden Age in space

    80% confidence
  • Healthcare is a market that desperately needs disruption, but it's also between regulation and it is life or death

    80% confidence
  • AI can absorb more real-time patient data than human doctors, such as Garmin watch health data integration

    80% confidence
  • Space investments are high-risk, high-reward

    80% confidence
  • AI has potential to remember/process more medical information than single human physician

    80% confidence
  • Rocket Lab wants to get Neutron launch right the first time, unlike SpaceX's iterative explosion approach

    80% confidence
  • Discussed data centers in space with solar power opportunity, more than 5 years away

    80% confidence
  • Prefers Rocket Lab over SpaceX, even if SpaceX was public

    80% confidence
  • Expected to move toward profitability in 2026

    80% confidence
  • Raised concerns about TransMedics Medicare reimbursement

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com